Medication info

Nephramin Injection

Prescription medicationInjectionsInjection
Ingredient · strength
L-Isoleucine›2.8g / 500mLL-Leucine›4.4g / 500mLL-Lysine Acetate›4.5g / 500mLL-Methionine›4.4g / 500mLL-Phenylalanine›4.4g / 500mLL-Threonine›2g / 500mLL-Valine›3.2g / 500mLL-Tryptophan›1g / 500mLL-Histidine›1.25g / 500mL
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
This drug is a colorless to pale yellow transparent injection in a polypropylene aqueous injection container.
Packaging
250mL/bag
Approval status
Active

MFDS item code 198501824 · Notified 1985.08.12 · Insurance code 644902352

Summary

Main use
Improvement of amino acid supplementation in acute and chronic renal failure
Who receives it
Adults · Children
Adult administration
○Adults: Generally, administer 250~500 mL per day intravenously by drip infusion (1.6~3.2 g as nitrogen, 13.4~26.8 g as essential amino acids). When a calorie source is administered at the same time, aseptically mix 250 mL of this drug with 500 mL of 70% glucose and use (diluted to 1.8% of this drug and 47% glucose). ○Infusion rate: Usually, start at 20~30 mL per hour and increase by 10 mL per hour every 24 hours until reaching a maximum of 60~100 mL per hour.
Child administration
○ Children: Start with a low total daily dose and increase it gradually. Do not administer more than 1 g of essential amino acids per kg of body weight per day.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Improvement of amino acid supplementation in acute and chronic renal failure

View approved original text

This drug is used to replenish amino acids in patients with acute and chronic renal failure. Renal failure can disrupt the balance of amino acids in the body, and replenishing these amino acids helps support bodily functions. Thus, it plays an important role in improving the symptoms of renal failure and maintaining nutritional status.

How it is given

Adult administration

○Adults: Generally, administer 250~500 mL per day intravenously by drip infusion (1.6~3.2 g as nitrogen, 13.4~26.8 g as essential amino acids). When a calorie source is administered at the same time, aseptically mix 250 mL of this drug with 500 mL of 70% glucose and use (diluted to 1.8% of this drug and 47% glucose). ○Infusion rate: Usually, start at 20~30 mL per hour and increase by 10 mL per hour every 24 hours until reaching a maximum of 60~100 mL per hour.

Child administration

○ Children: Start with a low total daily dose and increase it gradually. Do not administer more than 1 g of essential amino acids per kg of body weight per day.

Precautions

This medication must only be used according to a physician's instructions. It should not be used in patients with hepatic coma, severe electrolyte imbalance, reduced circulating blood volume, hyperammonemia, congenital amino acid metabolism disorders, symptomatic heart failure, and patients with fluid overload. Caution should be exercised when administering to patients with congestive heart failure, children, low birth weight infants, and patients with gastrointestinal bleeding, as allergic reactions or asthma attacks may occur due to the sodium bisulfite component. During administration, adverse reactions such as general itching, rash, nausea, vomiting, and palpitations may occur, so administration should be immediately stopped if any symptoms appear. Rapid administration of large amounts may lead to acidosis, and regular monitoring of liver function tests and blood urea and ammonia levels is necessary. This drug is mainly used to assist protein metabolism and is suitable for patients who are unable to take oral intake or for those on dialysis. Careful observation of hydration and electrolyte status is required during administration, and diabetic patients should pay attention to blood sugar control. Mixing this drug with other medications may be hazardous, so it must be administered according to an expert's instructions, and it is important to use it immediately after mixing. In the case of overdose, side effects or edema may occur, necessitating the reduction or cessation of administration. Since this drug contains electrolytes, care should be taken with electrolyte balance in the event of large volumes being administered, and it should be administered slowly intravenously to reduce side effects. To minimize the risk of infection during administration, sterility must be maintained, and solutions that are discolored or contaminated should not be used. Until the packaging is opened, care should be taken to prevent the solution from deteriorating, and any remaining solution after use should not be reused.

Side effects

  • generalized itching
  • rash
  • generalized urticaria
  • nausea
  • vomiting
  • loss of appetite
  • chest discomfort
  • palpitations
  • acidosis
  • elevated AST
Show 10 more
  • elevated ALT
  • elevated BUN
  • chills
  • fever
  • 热 sensation
  • burning sensation in the head
  • headache
  • vascular pain
  • thrombophlebitis
  • hyperammonemia

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent air from entering, and the storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius. By storing it this way, the effectiveness of the drug can be well maintained.

Appearance and packaging

Appearance

This drug is a colorless to pale yellow transparent injection in a polypropylene aqueous injection container.

Package unit

250mL/bag

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.